Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,394 result(s) found. Displaying page 1,438 of 2,220.
    «« First « Previous 1434  1435  1436  1437  1438  1439  1440  1441  1442  Next» Last»»
    EudraCT Number: 2004-004077-29 Sponsor Protocol Number: 2004112 Start Date*: 2005-02-04
    Sponsor Name:Procter & Gamble Pharmaceuticals
    Full Title: A Double-blind, Randomized, Multicenter, Active-control, 56-day Study with a 28-day Follow-up to Assess the Efficacy and Safety of RDP58 200 mg/day plus Mesalazine 2.4 g/day and RDP58 600 mg/day pl...
    Medical condition: Ulcerative colitis is characterized by acute and chronic inflammatory changes to the mucosa and submucosa of the colon and rectum. Clinical presentations include increased stool frequency, bloody d...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) SK (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003168-37 Sponsor Protocol Number: CAIN457ADE15 Start Date*: 2019-12-04
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, multicenter, 24-week study of subcutaneous secukinumab to assess anti-interleukin-17A treatment in plaque psoriasis patients with coexisting non-alcoholic fatty liver di...
    Medical condition: plaque psoriasis with coexisting non-alcoholic fatty liver disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003751-19 Sponsor Protocol Number: PCIA202/10 Start Date*: 2012-01-27
    Sponsor Name:PCI Biotech AS
    Full Title: An open-label, single arm, multi-centre, Phase II study to evaluate the safety and efficacy of PC-A11 with superficial and interstitial laser light application in patients with recurrent head and n...
    Medical condition: Recurrent head and neck squamous cell carcinoma (HNSCC) insuitable for surgery and radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002367-34 Sponsor Protocol Number: 29052016 Start Date*: 2016-09-30
    Sponsor Name:Hjertemedicinsk klinik, Rigshospitalet
    Full Title: Beta 3 agonist treatment in heart failure (BEAT-HF II)
    Medical condition: Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-000832-28 Sponsor Protocol Number: LWH0642 Start Date*: 2006-07-04
    Sponsor Name:Liverpool Women's NHS Foundation Trust
    Full Title: Dopamine pharmacokinetics in extremely premature infants: a pilot study
    Medical condition: Neonatal hypotension
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004279-30 Sponsor Protocol Number: SNT-III-012-E Start Date*: 2018-06-14
    Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited
    Full Title: A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: BE (Completed) GB (Prematurely Ended) FR (Ongoing) SE (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016703-35 Sponsor Protocol Number: NAPMSv3.2 Start Date*: 2010-01-08
    Sponsor Name:Dansk Multipel Sclerose Center
    Full Title: Natalizumabbehandling af progressiv multipel sklerose
    Medical condition: Secondary progressive multiple sclerosis and primary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063400 Secondary progressive multiple sclerosis LLT
    12.0 10063401 Primary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011170-15 Sponsor Protocol Number: P071226 Start Date*: 2009-08-10
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Evaluation de l'efficacité d'une corticothérapie à faible dose, associée à l'acide mycophénolique (Myfortic) dans le traitement d'attaque du syndrome néphrotique à lésions glomérulaires minimes de ...
    Medical condition: Syndrome néphrotique à lésions glomérulaires minimes (SNLGM).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029168 syndrome néphrotique à lésions glomérulaires minimes PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-005499-16 Sponsor Protocol Number: 2013-624 Start Date*: 2014-01-31
    Sponsor Name:Rigshospitalet, 2121
    Full Title: Pilot Study with Treatment of Short Bowel Syndrome Patients with end-jejunostomi with the Glucagon-Like Peptide-1 analogue, Liraglutide (Victoza®)
    Medical condition: Short Bowel Syndrome with intestinal failure (SBS IF)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004856 10022683 Intestinal malabsorption LLT
    16.1 100000004856 10036430 Post surgical malabsorption NOS LLT
    16.1 100000004856 10042822 Syndrome malabsorption LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002731-28 Sponsor Protocol Number: P12-01/BP1.4979 Start Date*: 2013-03-01
    Sponsor Name:Bioprojet
    Full Title: Randomized placebo controlled trial assessing the efficacy and safety of BP1.4979 in smoking cessation
    Medical condition: Smoking cessation
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004869 10008374 Cessation of smoking LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001505-17 Sponsor Protocol Number: BILA-3716/PRU Start Date*: 2016-07-29
    Sponsor Name:FAES FARMA, S.A.
    Full Title: An exploratory study to evaluate the efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases.
    Medical condition: Chronic spontaneous urticaria and the following skin disorders: 1 - Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, autosensitisation dermat...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10012435 Dermatitis and eczema HLT
    19.0 10040785 - Skin and subcutaneous tissue disorders 10037083 Prurigo PT
    19.0 10040785 - Skin and subcutaneous tissue disorders 10052568 Urticaria chronic PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-002972-15 Sponsor Protocol Number: Omalin-01 Start Date*: 2017-10-06
    Sponsor Name:Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
    Full Title: Ferrous Acetyl-Aspartylated Casein Formulation Evaluation over Ferrous Sulfate in Iron Deficiency Anemia (Access): A Double-Dummy Randomized Clinical Trial
    Medical condition: Iron deficiency anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003309-12 Sponsor Protocol Number: P100129 Start Date*: 2011-11-10
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10062282 Silver-Russell syndrome PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001391-15 Sponsor Protocol Number: V323Oct2020 Start Date*: 2020-04-24
    Sponsor Name:Royal College of Surgeons Ireland
    Full Title: A randomized double-blind placebo-controlled, pilot trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness.
    Medical condition: acute respiratory distress sydnrome (ARDS) secondary to Covid-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003033-41 Sponsor Protocol Number: 2005040 Start Date*: 2006-03-20
    Sponsor Name:Procter & Gamble Technical Centres Limited
    Full Title: A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomi...
    Medical condition: Osteoporosis is a systemic skeletal disorder characterized by low bone mass and micro-architectural deterioration of bone tissue leading to enhanced bone fragility and susceptibility to fracture. ...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10031285 PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001505-93 Sponsor Protocol Number: P11-11 Start Date*: 2013-12-19
    Sponsor Name:Bioprojet Pharma
    Full Title: A MULTI-CENTRE, SINGLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS OF PITOLISANT (BF2.649) IN CHILDREN FROM 6 TO LESS THAN 18 YEARS WITH NARCOLEPSY
    Medical condition: Narcolepsy
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10028713 Narcolepsy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-001684-22 Sponsor Protocol Number: UAM4 Start Date*: 2018-10-11
    Sponsor Name:University of Antwerp
    Full Title: A Phase 2, partial blind, randomized, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of two novel live attenuated serotype 2 oral poliovirus vaccines candidates, in...
    Medical condition: Poliomyelitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10036017 Poliomyelitis viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001179-39 Sponsor Protocol Number: 2005108 Start Date*: 2006-10-11
    Sponsor Name:Procter & Gamble Pharmaceuticals
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-group, Multicentre, 24 week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 mcg/day) in Naturally Menopausal Wome...
    Medical condition: Hypoactive sexual desire disorder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10020933 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000169-10 Sponsor Protocol Number: CUV101 Start Date*: 2011-04-08
    Sponsor Name:CLINUVEL PHARMACUETICALS LTD.
    Full Title: A Phase II, Randomised Pilot Study to Evaluate the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegm...
    Medical condition: Subjects affected by non-segmental vitiligo
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10062080 Pigmentation disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003166-14 Sponsor Protocol Number: RGB-02-101 Start Date*: 2013-11-20
    Sponsor Name:Gedeon Richter Plc.
    Full Title: Multiple, fixed-dose, comparative efficacy and safety evaluation of RGB-02 and Neulasta® in patients undergoing chemotherapy treatment known to induce neutropenia.
    Medical condition: Neutropenia and febrile neutropenia in patients being treated with cytotoxic chemotherapy for malignancy.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    16.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Elderly Gender: Female
    Trial protocol: CZ (Completed) HU (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1434  1435  1436  1437  1438  1439  1440  1441  1442  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 07 17:22:29 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA